Rallybio (RLYB) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Rallybio (RLYB) is Neutral.

The composite score behind that read is -0.06, weighing +0.19 of bullish evidence against -0.44 bearish.

Rallybio last closed at $17.02, +0.18% on the session.

Against the IVW growth benchmark the position is -0.62% over the forecast window.

The read is built from 11 underlying insights — 4 bullish and 7 bearish.

Agreement across those insights is 64%.

13 graded predictions for RLYB so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Rallybio in the 99th percentile on valuation and the 94th percentile on return on equity, where 100 is best.

Rallybio is classified under Health Care / Biotechnology, with a market capitalisation of $90.22M.

StockMap tracks Rallybio as the 288th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Rallybio ranks 175th of 381 in the group, against a group median of -0.08.